-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Frenlosirsen Sodium in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frenlosirsen Sodium in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frenlosirsen Sodium in Relapsed Multiple Myeloma Drug Details: IONISIRF4-2.5Rx is...
-
Product Insights
Burkholderia Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Burkholderia Infections - Drugs In Development, 2023’, provides an overview of the Burkholderia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
West Nile Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘West Nile Virus Infections - Drugs In Development, 2023’, provides an overview of the West Nile Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Dengue Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Dengue Fever - Drugs In Development, 2023’, provides an overview of the Dengue Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acinetobacter Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Acinetobacter Infections - Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FCN-437c in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FCN-437c in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FCN-437c in Solid Tumor Drug Details:FCN-437c is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rovaleucel in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rovaleucel in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Rovaleucel in Nasopharyngeal CancerDrug Details:Rovaleucel (TT-10) is under development for the treatment of...